PMID- 23726596
OWN - NLM
STAT- MEDLINE
DCOM- 20131230
LR  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Increased plasma tissue inhibitors of metalloproteinase concentrations as 
      negative predictors associated with deterioration of kidney allograft function 
      upon long-term observation.
PG  - 1458-61
LID - S0041-1345(13)00327-8 [pii]
LID - 10.1016/j.transproceed.2013.02.109 [doi]
AB  - Chronic allograft injury (CAI) is the most frequent cause of progressive kidney 
      allograft impairment and eventual loss, which is due to interstitial fibrosis and 
      tubular atrophy (IF/TA). Mechanisms of CAI are not fully understood. Chemokines, 
      cytokines, metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases 
      (TIMPs) play roles in fibrosis development. The aims of this study were to 
      evaluate plasma and urine TIMPs (TIMP-1 and TIMP-2), MMPs (MMP-2 and MMP-9), 
      proinflammatory interleukin-6 (IL-6), chemokine (C-C motif) ligand 2 (CCL2 
      chemokines previously known as monocyte chemoattractant protein-1 [MCP-1]) among 
      150 recipients beyond 1 year post-renal transplantations and to explore the 
      usefulness of these potential biomarkers of ongoing allograft injury. Renal 
      transplant recipients compared with healthy volunteers (control group) showed 
      significantly increased plasma and urine IL-6, MMP-9, TIMP-1, and TIMP-2, as well 
      as lower plasma MMP-2 and urine CCL2 concentrations. Compared with recipients 
      showing good function those with impairments displayed higher plasma TIMP-1 (P < 
      .001) and TIMP-2 (P = .003) concentrations. The recipient estimated glomerular 
      filtration rate (eGFR) values negatively correlated with plasma TIMP-1 and TIMP-2 
      levels (r = -0.43; P < .0001 and rs = -0.42; P < .0001, respectively) and with 
      urine IL-6 excretion (rs = -0.33; P < .0001). Multivariate and receiver operating 
      characteristic (ROC) analyses showed TIMP-1 plasma level assessments to be useful 
      estimates of allograft injury.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Mazanowska, O
AU  - Mazanowska O
AD  - Department of Nephrology and Transplantation Medicine, Wroclaw Medical 
      University, Wroclaw, Poland. o.mazanowska@gmail.com
FAU - Kaminska, D
AU  - Kaminska D
FAU - Krajewska, M
AU  - Krajewska M
FAU - Banasik, M
AU  - Banasik M
FAU - Zabinska, M
AU  - Zabinska M
FAU - Koscielska-Kasprzak, K
AU  - Koscielska-Kasprzak K
FAU - Biecek, P
AU  - Biecek P
FAU - Chudoba, P
AU  - Chudoba P
FAU - Patrzalek, D
AU  - Patrzalek D
FAU - Boratynska, M
AU  - Boratynska M
FAU - Klinger, M
AU  - Klinger M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
SB  - IM
MH  - Adult
MH  - Female
MH  - Glomerular Filtration Rate
MH  - *Graft Rejection
MH  - Humans
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - Tissue Inhibitor of Metalloproteinases/*blood
EDAT- 2013/06/04 06:00
MHDA- 2014/01/01 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/11/26 00:00 [received]
PHST- 2013/02/08 00:00 [revised]
PHST- 2013/02/27 00:00 [accepted]
PHST- 2013/06/04 06:00 [entrez]
PHST- 2013/06/04 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
AID - S0041-1345(13)00327-8 [pii]
AID - 10.1016/j.transproceed.2013.02.109 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1458-61. doi: 10.1016/j.transproceed.2013.02.109.